RASSEGNA STAMPA ESTERA/WEB
gennaio febbraio marzo aprile maggio giugno luglio agosto settembre ottobre novembre dicembre
Cliccare sulle immagini per ingrandirle
|Russia to Test its Most Powerful Intercontinental Ballistic Missile 'Sarmat' in 2021|
|Da defenseworld.net del 31 marzo 2021|
“Right now the main work to be done in the near future is preparing for flight tests of Sarmat heavy ICBM,” Dmitry Rogozin, head of Roscosmos, said during his speech at Korolyevskiy in Moscow.
Moscow claims the missile can “tear any current anti-aircraft missile defense systems to shreds.”
In December 2020, Deputy Defense Minister Alexei Krivoruchko disclosed that Sarmat was about to enter flight trials.
The RS-28 Sarmat (SS-X-30 Satan II) is an advanced silo-based system with a heavy liquidpropellant intercontinental ballistic missile. It has been in the process of its development since the 2000s to replace the R-36M2 Voyevoda (SS-18 Satan) ICBM. It weighs about 200 tonnes and has a payload of around 10 tonnes. Russia claims that the missile has a range of 10,000-18,000 km.
According to Russian media, Sarmat can reportedly load up to 10 large warheads, 16 smaller ones, a combination of warheads and countermeasures, or hypersonic boost-glide vehicles.
|Russia Working on New Strategic Missile System|
|Da defenseworld.net del 1 marzo 2021|
Kedr missile system (via Russian MoD)
Russia has launched a project to develop a new-generation strategic missile system named Kedr.
The project is currently in the research and development phase, a source in the rocket and space industry was quoted as saying by TASS (https://tass.com/defense/1261243) today.
The Russian military is currently armed with Topol, Topol-M and Yars intercontinental ballistic missiles. Nuclear strategic submarines of projects 955 and 955A are armed with Bulava strategic missiles. The forces will also gradually adopt the Avangard hypersonic missiles.
In December 2020, Deputy Defense Minister Alexei Krivoruchko disclosed that the Sarmat heavy missile was about to enter flight trials.